The changing perspective on cardiac amyloidosis in the modern era

References

[1] Porcari A,Rossi M.Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy.Eur Heart J Case Rep2022;6:ytac130 PMCID:PMC9149786

[2] Porcari A,Rapezzi C.Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery.Eur J Intern Med2020;82:7-15 PMCID:PMC7534738

[3] Porcari A,Merlo M.Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination.Front Cardiovasc Med2021;8:749523 PMCID:PMC8649842

[4] De Gaspari M,Basso C.Cardiac amyloidosis: the pathologist’s point of view.Vessel Plus2022;5:[Accept]

[5] Aimo A,Porcari A.Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.Eur J Heart Fail2022;Online ahead of print:

[6] Canepa M,Porcari A,Scarpa M.Cardiac amyloidosis: a changing epidemiology with open challenges.Vessel Plus2022;6:30

[7] Merlo M,Porcari A.Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey.Eur J Heart Fail2022;Online ahead of print:

[8] Porcari A,Longo F.Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery.ESC Heart Fail2022;9:751-60 PMCID:PMC8787962

[9] Gillmore JD,Falk RH.Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation2016;133:2404-12

[10] Porcari A,Dore F.Ten questions for the cardiologist about cardiac scintigraphy with bone tracers, amyloidosis and the heart.G Ital Cardiol (Rome)2022;23:424-32

[11] Mattana F,Girardi F.Clinical application of cardiac scintigraphy with bone tracers: controversies and pitfalls in cardiac amyloidosis.Vessel Plus2022;6:13

[12] Bishop E,Fajardo J,Judge DP.Seven factors predict a delayed diagnosis of cardiac amyloidosis.Amyloid2018;25:174-9

[13] Pica S.Disclosing the cardiomyopathic substrate within the heart muscles in amyloidosis by cardiac magnetic resonance: diagnostic and prognostic implications.Vessel Plus2022;6:10

[14] Genovesi D.Nuclear medicine techniques for the diagnosis of cardiac amyloidosis: the state of the art.Vessel Plus2021;5:50

[15] Porcari A,Cappelli F.Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.Eur J Heart Fail2022;24:1227-36

[16] Porcari A,Varrà GG.Grey zones in the supportive treatments of cardiac amyloidosis.Vessel Plus2022;6:33

[17] Scirpa R,Tini G.Clinical translation of genetic testing in TTR amyloidosis: genotype-phenotype correlations, management of asymptomatic carriers and familial screening.Vessel Plus2022;6:[Accept]

[18] Camerini L,Pucci A.Serum and tissue light-chains as disease biomarkers and targets for treatment in AL amyloidosis.Vessel Plus2022;6:[Accept]

[19] Licordari R,Cappelli F.Mid-basal left ventricular longitudinal dysfunction as a prognostic marker in mutated transthyretin-related cardiac amyloidosis.Vessel Plus2022;6:12

[20] Zhang KW,Lenihan DJ.Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis.JACC Basic Transl Sci2019;4:438-48 PMCID:PMC6609907

[21] Di Nora C,Nalli C.Heart transplantation in cardiac amyloidosis.Vessel Plus2022;6:[Accept]

[22] Di Nora C,Ferrara V.Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation.J Cardiovasc Med (Hagerstown)2021;22:261-7